The global chemotherapy-induced nausea and vomiting drugs market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The term chemotherapy-induced nausea and vomiting includes emesis and nausea, which can involve a loss of appetite and result in the decreased oral intake of fluids and calories. Therefore, for the management of such conditions, the demand for chemotherapy-induced nausea and vomiting drugs is likely to grow in the near future. Further, the growing geriatric population along with the rising prevalence of cancer are acting as the pivotal factors responsible for the increased demand for these drugs.
Get Free Sample link @ https://www.omrglobal.com/request-sample/chemotherapy-induced-nausea-and-vomiting-drugs-market
The global chemotherapy-induced nausea and vomiting drugs market is also driven by extensive R&D along with new FDA approvals. For instance, in April 2021, Caplin Steriles has been granted final approval from the US FDA for its abbreviated new drug application (ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials. Prochlorperazine edisylate injection is a drug that is indicated for the control of severe nausea and vomiting.
Some major key players in the market include Novartis International AG, F. Hoffman La-Roche AG, and Merck & Co., Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion. HTX-019 injectable emulsion is intended to be used for the prevention of postoperative nausea and vomiting (PONV) in adults.
Full report of Chemotherapy-Induced Nausea and Vomiting Drugs Market available @ https://www.omrglobal.com/industry-reports/chemotherapy-induced-nausea-and-vomiting-drugs-market
Market Coverage
Segment Covered-
- By Type
- By Therapy
- By Drug Type
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Novartis International AG, F. Hoffman La-Roche AG, and Merck & Co., Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report by Segment
By Type
- Acute Emesis
- Delayed Emesis
- Anticipatory Emesis
- Refractory Emesis
By Therapy
- Nk-1 Receptor Antagonist
- Serotonin Receptor Antagonist
- Others
By Drug Type
- Branded
- Generics
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/chemotherapy-induced-nausea-and-vomiting-drugs-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.